Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10985427 | PMC |
| http://dx.doi.org/10.3324/haematol.2023.283864 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Characteristics, outcomes and treatment patterns in acute myeloid leukemia patients 60 years or older in Colombia: a RENEHOC-PETHEMA study.
Ann Hematol
January 2025
Hematology Unit, Hospital Universitari i Politècnic La Fe, Valencia, España.
There is a limited information available on the clinical characteristics, treatment patterns and outcomes on older patients diagnosed with Acute Myeloid Leukemia (AML) in Latin-America. This multicenter retrospective study analyzed 269 patients over 60 years of age diagnosed with AML in Colombia, using data from RENEHOC-PETHEMA registry, from 2009 to 2023. The median age at diagnosis was 70 years (Range:60-98), 55% were men, 61% had an ECOG < 2, and 75.
View Article and Find Full Text PDFComplex Genetic Evolution and Treatment Challenges in Myeloid Neoplasms: A Case of Persistent t(2;3)(p15~23;q26)/ Rearrangement, Mutation, and Transient Chimera.
Cancer Genomics Proteomics
December 2024
Section for Cancer Cytogenetics, Institute for Cancer Genetics and Informatics, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway;
Background/aim: Myelodysplastic syndromes (MDSs) are clonal bone marrow disorders characterized by ineffective hematopoiesis. They are classified based on morphology and genetic alterations, with SF3B1 variants linked to favorable prognosis and MECOM rearrangements associated with poor outcomes. The combined effects of these alterations remain unclear.
View Article and Find Full Text PDF5-Aza-2'-deoxycytidin (Decitabine) increases cancer-testis antigen expression in head and neck squamous cell carcinoma and modifies immune checkpoint expression, especially in CD39-positive CD8 and CD4 T cells.
Neoplasia
January 2025
Head and Neck Cancer Center of the Comprehensive Cancer Center, Department of Otorhinolaryngology and Head & Neck Surgery, Ulm University Medical Center, Germany; Ulm University Medical Faculty, Core Facility Immune Monitoring, Ulm, Germany. Electronic address:
Failure of immunotherapy in head and neck squamous cell carcinoma (HNSCC) patients represents an unmet need to augment leverage of adaptive immunity. Immunogenic cancer-testis antigen (CTA) expression as well as lymphocyte differentiation and function are regulated by DNA methylation. Therefore, epigenetic therapy via inhibition of DNA-Methyltransferases by 5-Aza-2'-deoxycytidine (DAC) serves a promising adjuvant in immunotherapy.
View Article and Find Full Text PDFVenetoclax with low-dose cytarabine, a forgotten combination in patients with acute myeloid leukemia ineligible for intensive chemotherapy: a systematic review.
Hematol Transfus Cell Ther
December 2024
Department of Medicine and Nutrition, University of Guanajuato, Leon, Guanajuato, Mexico.
Background: Based on the VIALE-A and VIALE-C studies, the Food and Drug Administration approved venetoclax in 2020 in combination with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia ineligible for intensive chemotherapy. After the publication of these studies, venetoclax/azacitidine was assumed to be superior to venetoclax/low-dose cytarabine; however, these studies were not designed to demonstrate superiority between these combinations. Therefore, we conducted a systematic review to describe overall survival, complete remission rate, and composite complete remission rate to assess response of these two regimens in patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy.
View Article and Find Full Text PDFRecurrent, multisystem angioedema induced by 5-azacitidine.
J Oncol Pharm Pract
October 2024
Lucy Curci Cancer Center, Eisenhower Health, Rancho Mirage, CA, USA.
Article Synopsis
- 5-azacitidine is a treatment for myelodysplastic syndrome (MDS) and certain myeloproliferative neoplasms (MPNs), but it can cause side effects like myelosuppression and nausea, with rare, serious allergic reactions.
- A case study describes a 71-year-old man with MDS/MPN who experienced repeated episodes of angioedema after starting 5-azacitidine, affecting various body areas and deemed causally linked to the medication.
- After discontinuing 5-azacitidine due to ongoing angioedema, the patient responded well to steroids and is now managing his blood condition with low-dose hydroxyurea, while the exact cause
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!